Greenwich LifeSciences, Inc. (GLSI )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol GLSI
- Company Greenwich LifeSciences, Inc.
- Price $16.32
- Changes Percentage -14.15
- Change -2.69
- Day Low $15.9
- Day High $19.04
- Year High $34.1
- Year Low $7.78
- Market Cap $356,533,672
- Price Avg 50 EMA (D) $24.95
- Price Avg 200 EMA (D) $18.52
- Exchange NASDAQ
- Volume 118,372
- Average Volume 155,680
- Open $19.04
- Previous Close $19.01
- EPS -1.43
- PE -16.99
- Earnings Announcement 2026-06-01 04:00:00
- Shares Outstanding $14,678,208
Company brief: GREENWICH LIFESCIENCES, INC. (GLSI )
- Healthcare
- Biotechnology
- Mr. Snehal S. Patel
- https://greenwichlifesciences.com
- US
- N/A
- 09-25-2020
- US3968791083
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.